Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation

Journal of Neurochemistry

Volumn 106, Issue 2, 2008, Pages 560-577

  Bellucci, Arianna ^a   Collo, Ginetta ^a   Sarnico, Ilenia ^a   Battistin, Leontino ^b   Missale, Cristina ^a   Spano, Pierfranco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

synuclein; D2 D3 receptor agonists; Dopamine overload; Dopamine transporter; Glucose deprivation; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE UPTAKE INHIBITOR; GLUCOSE; QUINPIROLE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FORMAZAN; MTT FORMAZAN; NERVE PROTEIN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIOFLAVINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CONTROLLED STUDY; EMBRYO; ENERGY; ENERGY METABOLISM; GLUCONEOGENESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; MOUSE; NERVE CELL; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NUTRITIONAL DEFICIENCY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; EMBRYO (ANATOMY); GENE EXPRESSION REGULATION; MESENCEPHALON; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; CELL DEATH; CELLS, CULTURED; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EMBRYO, MAMMALIAN; FORMAZANS; GENE EXPRESSION REGULATION; GLUCOSE; MESENCEPHALON; MICE; MITOCHONDRIA; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURONS; PROTEIN TRANSPORT; RECEPTORS, DOPAMINE D2; TETRAZOLIUM SALTS; THIAZOLES;

EID: 51649089030     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05406.x     Document Type: Article

References (42)

1. Ambani L. M., Van Woert M. H. and Murphy S. (1975) Brain peroxidase and catalase in Parkinson disease. Arch. Neurol. 32, 114-118.
2. Armentero M. T., Fancellu R., Nappi G. and Blandini F. (2002) Dopamine receptor agonists mediate neuroprotection in malonate- induced striatal lesion in the rat. Exp. Neurol. 178, 301-305.
3. Boecker H., Weindl A., Leenders K., Antonini A., Kuweit T., Kruggel F., Grafin v. E. and Conrad B. (1996) Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta Neurol. Scand. 93, 387-392.
4. Bolan E. A., Kivell B., Jaligam V. et al. (2007) D2 receptors regulate dopamine transporter function via an ERK 1/2-dependent and PI3 kinase-independent mechanism. Mol. Pharmacol. 71, 1222-1232.
5. Bowling A. C. and Beal M. F. (1995) Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56, 1151-1171.
6. Braak H., Bohl J. R., Muller C. M., Rub U., de Vos R. A. and Del Tredici K. (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21, 2042-2051.
7. Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349.
8. Counihan T. J. and Penney J. B. Jr (1998) Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains. J. Neurol. Neurosurg. Psychiatry 65, 164-169.
9. Emdadul H. M., Asanuma M., Higashi Y., Miyazaki I., Tanaka K. and Ogawa N. (2003) Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblas- toma cells. Biochim. Biophys. Acta 1619, 39-52.
10. Fahn S. (2005) Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. 252(Suppl. 4), IV37-IV42.
11. FahnS., OakesD., Shoulsonl., KieburtzK., Rudolph A., Lang A., Olanow C. W., Tanner C. and Marek K. (2004) Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498-2508.
12. Fukae J., Mizuno Y. and Hattori N. (2007) Mitochondrial dysfunction in Parkinson's disease. Mitochondrion 7, 58-62.
13. Guatteo E., Marinelli S., Geracitano R., Tozzi A., Federici M., Bernardi G. and Mercuri N. B. (2005) Dopamine-containing neurons are silenced by energy deprivation: a defensive response or beginning of cell death? Neurotoxicology 26, 857-868.
14. Harrington K. A., Augood S. J., Kingsbury A. E., Foster O. J. and Emson P. C. (1996) Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the sub- stantia nigra of control and Parkinson's disease. Brain Res. Mol. Brain Res. 36, 157-162.
15. Hornykiewicz O. (1998) Biochemical aspects of Parkinson's disease. Neurology 51, S2-S9.
16. Isaev N. K., Stel'mashuk E. V. and Zorov D. B. (2007) Cellular mechanisms of brain hypoglycemia. Biochemistry (Mosc.) 72, 471-478.
17. Kish S. J., Morito C. and Hornykiewicz O. (1985) Glutathione peroxi- dase activity in Parkinson's disease brain. Neurosci. Lett. 58, 343-346.
18. Kitamura Y., Ishida Y., Takata K., Kakimura J., Mizutani H., Shimohama S., Akaike A. and Taniguchi T. (2001) Alpha-synuclein protein is not scavenged in neuronal loss induced by kainic acid or focal ischemia. Brain Res. 898, 181-185.
19. Lee F. J., Liu F., Pristupa Z. B. and Niznik H. B. (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926.
20. Lee F. J., Pei L., Moszczynska A., Vukusic B., Fletcher P. J. and Liu F. (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J. 26, 2127-2136.
21. Lotharius J. and Brundin P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932-942.
22. Ma Y. and Eidelberg D. (2007) Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Hun- tington's disease. Mol. Imaging Biol. 9, 223-233.
23. Marttila R. J., Lorentz H. and Rinne U. K. (1988) Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86, 321-331.
24. Ono K., Hirohata M. and Yamada M. (2007) Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha- synuclein fibrils in vitro. J. Neurosci. Res. 85, 1547-1557.
25. Pennypacker K. R., Kuhn D. M. and Billingsley M. L. (1989) Changes in expression of tyrosine hydroxylase immunoreactivity in human SMS-KCNR neuroblastoma following retinoic acid or phorbol ester- induced differentiation. Brain Res. Mol. Brain Res. 5, 251-258.
26. Perrin R. J., Payton J. E., Barnett D. H., Wraight C. L., Woods W. S., Ye L. and George J. M. (2003) Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci. Lett. 349, 133-135.
27. Presgraves S. P., Ahmed T., Borwege S. and Joyce J. N. (2004) Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox Res 5, 579-598.
28. Qin Y., Ouyang Q., Pablo J. and Mash D. C. (2005) Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum. Neuroreport 16, 1489-1493.
29. Radad K., Gille G. and Rausch W. D. (2005) Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol. Rep. 57, 701-712.
30. Reider-Groswasser I., Bornstein N. M. and Korczyn A. D. (1995) Parkinsonism in patients with lucanar infarcts of the basal ganglia. Eur. Neurol. 35, 46-49.
31. Saggu H., Cooksey J., Dexter D., Wells F. R., Lees A., Jenner P. and Marsden C. D. (1989) A selective increase in particulate super- oxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53, 692-697.
32. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., Kimura J. and Shimohama S. (1998) Dopamine D2-type agonists protect me- sencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44, 110-119.
33. Schapira A. H. (2007) Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ. 14, 1261-1266.
34. Sian J., Dexter D. T., Lees A. J., Daniel S., Jenner P. and Marsden C. D. (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356-361.
35. Studer L. (1997) Current Protocols in Neuroscience, pp. 3.3.1-3.3.12.
36. Sulzer D. and Zecca L. (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1, 181-195.
37. Szczudlik A. and Rudzinska M. (2007) Neuroprotective effect of dopamine agonists. Neurol. Neurochir. Pol. 41, S22-S28.
38. Tofaris G. K. and Spillantini M. G. (2005) Alpha-synuclein dysfunction in Lewy body diseases. Mov. Disord. 20(Suppl. 12), S37-S44.
39. Tofaris G. K. and Spillantini M. G. (2007b) Physiological and pathological properties of alpha-synuclein. Cell. Mol. Life Sci. 64, 280-282.
40. Tofaris G. K., Garcia R. P., Humby T. et al. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein (1-120): implications for Lewy body disorders. J. Neurosci. 26, 3942-3950.
41. Uversky V. N. (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 103, 17-37.
42. Wersinger C., Prou D., Vernier P. and Sidhu A. (2003) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151-2153.